Researchers Identify Key Regulator of NKT Cell Therapy for Cancer

Strategic Insights -

Researchers at Texas Children's Cancer & Hematology Center have identified a crucial regulator of natural killer T (NKT) cell therapy for cancer treatment. The team developed a CRISPR/Cas9-based mutagenesis screen, which revealed that PRDM1, a transcription factor, plays a vital role in regulating NKT cell memory differentiation and effector function. The study's findings suggest that PRDM1 could be targeted to improve the efficacy of NKT-based cancer immunotherapies.

Key Takeaways:

  • The researchers developed a CRISPR/Cas9-based mutagenesis screen to identify regulators of NKT therapeutic activity, targeting 1,118 immune-related genes.
  • The study found that PRDM1 was significantly enriched in NKT cells and GD2.CAR NKT cells, and its knockout resulted in central memory-like differentiation and reduced exhaustion.
  • However, PRDM1 knockout also led to reduced in vitro cytotoxicity and moderate in vivo antitumor activity in a xenogeneic neuroblastoma model.
  • Short hairpin RNA-mediated PRDM1 knockdown preserved effector function and promoted central memory differentiation, leading to GD2.CAR NKT cells with potent in vivo antitumor activity.
  • The study concluded that PRDM1 is a key regulator of NKT memory differentiation and effector function, which can be exploited to improve the efficacy of NKT-based cancer immunotherapies.

Statistics:

  • The CRISPR/Cas9-based mutagenesis screen targeted 1,118 immune-related genes.
  • PRDM1 was enriched in NKT cells and GD2.CAR NKT cells by 2.5-fold and 3.2-fold, respectively.
  • The study used a gRNA library to transduce NKT cells and GD2.CAR NKT cells, exposing them to CD1d-positive leukemia or CD1d-GD2-positive neuroblastoma cells in vitro.
  • The study used a xenogeneic neuroblastoma model to evaluate the in vivo antitumor activity of GD2.CAR NKT cells with PRDM1 knockout.

Sources:

  • Metelitsa, L. et al. (2025). prdm1 Is a Key Regulator of the Nkt-cell Central Memory Program and Effector Function. Cancer Immunology Research, 13(4), 577-590.
  • NewsRx. Researchers from Texas Children's Cancer & Hematology Center Describe Findings in Pain and Central Nervous System (prdm1 Is a Key Regulator of the Nkt-cell Central Memory Program and Effector Function). Immunotherapy Weekly, May 21, 2025; p 3496.